Update of insulin-like growth factor-Ⅰ receptor and its role in Graves′ orbitopathy
10.3760/cma.j.cn311282-20200212-00059
- VernacularTitle:胰岛素样生长因子Ⅰ受体及其在Graves眼病中作用研究进展
- Author:
Yingchai ZHANG
1
;
Shuhang XU
;
Chao LIU
Author Information
1. 南京中医药大学附属中西医结合医院内分泌科 210028
- From:
Chinese Journal of Endocrinology and Metabolism
2020;36(9):799-802
- CountryChina
- Language:Chinese
-
Abstract:
Graves′ orbitopathy is one of the complications related to Graves′ disease. Currently, there is still no available medical therapy provides reliable and safe benefit. Basic and clinical researches on insulin-like growth factor-Ⅰ(IGF-Ⅰ)receptor have found that IGF-Ⅰ receptor has implicated in the pathogenesis of Graves′ orbitopathy. As an IGF-Ⅰ receptor monoclonal antibody, teprotumumab was recently approved for this indication in the United States. It suggested that the therapy targeting on IGF-Ⅰ receptor pathway will soon take its place in the therapeutic armamentarium for active Graves′ orbitopathy.
